Scientific leader role to own end-to-end biomarker and translational strategy across a portfolio of inflammatory bowel disease (IBD) and liver programs.
Responsibilities
Own and continuously evolve the integrated GI/IBD and liver biomarker and translational strategy across multiple clinical-stage assets, aligning evidence generation with disease-area, asset, regulatory and portfolio objectives.
Lead the most complex programs from early clinical development through Phase II/III, defining decision criteria for target engagement, dose, proof-of-concept, patient selection, response, safety, differentiation and lifecycle opportunities.
Provide hands-on scientific leadership for analysis and interpretation of blood, stool, intestinal and liver tissue, endoscopic, histologic, imaging, pathology and multi-omic datasets.
Create cross-asset frameworks for forward and reverse translation, including integrated biopsy strategies and analyses of response, resistance, relapse, patient heterogeneity and mechanisms of action.
Lead biomarker and translational contributions to protocols, analysis plans, investigator brochures, clinical study reports, briefing documents, regulatory submissions and health authority interactions.
Requirements
PhD, MD, MD/PhD, PharmD or equivalent advanced degree in immunology, gastroenterology, hepatology, inflammation biology, translational medicine, pharmacology or a related discipline